Latest news and insights on the pharmaceutical industry | Indian Pharma Post

Results For "Nipah"

6 News Found

Nipah survivors study to advance new vaccines against highly fatal threat
Biotech | March 16, 2022

Nipah survivors study to advance new vaccines against highly fatal threat

CEPI will expand its partnership with icddr,b in Bangladesh, providing near to the additional US $ 1 million in funding to advance understanding of the Nipah virus


DCGI grants EUA to Truenat for conducting Nipah virus tests
Digitisation | September 09, 2021

DCGI grants EUA to Truenat for conducting Nipah virus tests

Nipah virus (NiV) is an emerging zoonotic disease that causes severe disease in humans. Signs and symptoms range from asymptomatic to acute respiratory infection and fatal encephalitis


Cabinet approves post of director for National Institute for One Health
Policy | March 02, 2024

Cabinet approves post of director for National Institute for One Health

The National One Health Mission will help India to achieve integrated disease control and pandemic preparedness


IAVI and Moderna launch first-in-Africa clinical trial of mRNA HIV vaccine
Biotech | May 19, 2022

IAVI and Moderna launch first-in-Africa clinical trial of mRNA HIV vaccine

Phase I trial in Rwanda and South Africa aims to evaluate mRNA HIV vaccine antigen for safety and immunogenicity and strengthen regional scientific capacity


Moderna to set up first mRNA facility in Kenya
News | March 08, 2022

Moderna to set up first mRNA facility in Kenya

The company is investing up to US $ 500 million to produce up to 500 million doses each year for the African continent


Molbio has pioneered point of care molecular testing: Sriram Natarajan
interviews | November 22, 2021

Molbio has pioneered point of care molecular testing: Sriram Natarajan

Molbio Diagnostics has been the pioneer in providing access to molecular testing through its Truenat Real Time PCR platform. Sriram Natarajan, Director & CEO, of the company shares his experiences on the journey so far in an interview with Thomas C Thottathil